Peschel R E, Fogel T D, Kacinski B M, Kelly K, Mate T P
Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1777-81. doi: 10.1016/0360-3016(85)90031-8.
One hundred-thirteen patients underwent Iodine-125 prostate implant and lymphadenectomy at Yale-New Haven Hospital from 1974 through 1980. The distribution by clinical stage was: 7 Stage A2, 86 Stage B, and 20 Stage C patients. Ninety-four patients had a negative lymphadenectomy (N-) and 19 patients (17%) had metastatic disease in the pelvic lymph nodes (N+). The actuarial 5-year survival for all 113 patients was 87% (+/- 6%: 95% confidence limits). Sixty-five percent of our 113 patients are disease free (NED) from 2 to 9 years following implant. Sixty-seven (N-) patients with clinical Stage B disease, whose tumors were either well differentiated or moderately well differentiated, have an actuarial 5-year NED survival of 84% (+/- 8%). Twenty (N-) patients with either clinical Stage C disease or poorly differentiated tumors have an actuarial 5-year NED survival of only 31% (+/- 20%). For the 19 (N+) patients, the actuarial 5-year NED survival is 38% (+/- 22%). Local tumor control was 85% for all Stage B patients and 75% for all Stage C patients. Only 10 patients (9%) have developed long-term gastrointestinal or genitourinary complications following their implant. Iodine-125 implant appears to be a reasonable alternate form of therapy in highly selected groups of patients with carcinoma of the prostate.
1974年至1980年间，113例患者在耶鲁-纽黑文医院接受了碘-125前列腺植入及淋巴结清扫术。临床分期分布如下：7例A2期、86例B期和20例C期患者。94例患者淋巴结清扫结果为阴性（N-），19例患者（17%）盆腔淋巴结有转移病灶（N+）。113例患者的5年精算生存率为87%（±6%：95%置信区间）。113例患者中有65%在植入后2至9年无疾病（NED）。67例临床B期（N-）患者，其肿瘤为高分化或中分化，5年精算NED生存率为84%（±8%）。20例临床C期（N-）患者或低分化肿瘤患者的5年精算NED生存率仅为31%（±20%）。19例（N+）患者的5年精算NED生存率为38%（±22%）。所有B期患者的局部肿瘤控制率为85%，所有C期患者为75%。仅10例患者（9%）在植入后出现了长期胃肠道或泌尿生殖系统并发症。碘-125植入术似乎是高度选择的前列腺癌患者群体中一种合理的替代治疗方式。
